Lilly Ending Trial For Experimental Arthritis Treatment

Lilly Ending Trial For Experimental Arthritis Treatment
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is stopping a late-stage trial for a potential rheumatoid arthritis treatment. Lilly says the decision was not made out of safety concerns and the experimental drug is still involved in two other Phase 3 …

Full News here – Read more on Inside INdiana Business (press release)

Leave a Reply